Drug intelligence / Profile preview

Oulogram

Development stage: Unknown
Lead developer: NI-THE
Modality: Small Molecules
Administration: Buccal

Overview

**Oulogram** is an approved NI-THE oral antiseptic fixed-dose combination containing sodium borate, tannic acid, thymol, and tyrothricin for oral infections. Its local antimicrobial activity is principally supported by tyrothricin, a polypeptide antibiotic mixture with membrane-disrupting activity against susceptible bacteria, together with the antiseptic properties of thymol and sodium borate; tannic acid provides local astringent activity. NI-THE identifies Oulogram as a dental product and lists the product composition as tyrothricine, thymol, tannine, and sodium borate. ([ni-the.com](https://ni-the.com/en/))

Brand names: Oulogram
Other names: borax + tannic acid + thymol + tyrothricin

Targets

Mpro (3C-like proteinase of SARS-CoV-2)TMPRSS2 (Transmembrane protease serine 2)AcetylcholinesteraseNeuraminidaseGLB1 (Galactosidase Beta 1)

Beyond the preview

Go deeper on Oulogram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oulogram.